ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Clinical trials from which the Breast Cancer Index data are drawn

Clinical trials from which the Breast Cancer Index data are drawn
Citation Trial name Intervention
Zhang Y, et al[1] Stockholm Tam Tamoxifen for 2 versus 5 years versus nothing (tamoxifen 2 and 5 years combined in analysis)
Sgroi DC, et al[2] MA17 Tamoxifen for 5 years, then letrozole versus placebo (extended; case control)
Sgroi DC, et al[3] ATAC Tamoxifen versus anastrozole versus combined (combined not included in analysis)
Sestak I, et al[4] ATAC
Bartlett JM, et al[5] aTTom Tamoxifen at least 4 years, then tamoxifen versus nothing (extended; only the node positive)
Bartlett JM, et al[6] aTTom
Sgroi DC, et al[7] aTTom
Noordhoek I, et al[8] IDEAL Tamoxifen or tamoxifen-aromatase inhibitor or aromatase inhibitor for 5 years, then 2.5 versus 5 years of letrozole (extended)
Mamounas EP, et al[9] B-42 Endocrine therapy for 5 years, then letrozole versus placebo (extended)
References:
  1. Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013; 19:4196.
  2. Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013; 105:1036.
  3. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14:1067.
  4. Sestak I, Buus R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018; 4:545.
  5. Bartlett JM, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol 2019; 30:1776.
  6. Bartlett JM, Sgroi DC, Treuner K, et al. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res 2022; 28:1871.
  7. Sgroi DC, Treuner K, Zhang Y, et al. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Ca Res 2022; 24:90.
  8. Noordhoek I, Treuner K, Putter H, et al. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res 2021; 27:311.
  9. Mamounas EP, Bandos H, Rastogi P, et al. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. J Clin Oncol 2021; 39:S501.
Graphic 143117 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟